Literature DB >> 28003112

Study of Duchenne muscular dystrophy long-term survivors aged 40 years and older living in specialized institutions in Japan.

Toshio Saito1, Mitsuru Kawai2, En Kimura3, Katsuhisa Ogata2, Toshiaki Takahashi4, Michio Kobayashi5, Hiroto Takada6, Satoshi Kuru7, Takashi Mikata8, Tsuyoshi Matsumura9, Naohiro Yonemoto3, Harutoshi Fujimura9, Saburo Sakoda9.   

Abstract

The national muscular dystrophy wards database of Japan lists 118 long-term Duchenne muscular dystrophy (DMD) patients who were at least 40 years old as of October 1, 2013. To elucidate the clinical features of DMD patients aged 40 years and older, we obtained gene analysis and muscle biopsy findings, as well as medical condition information. Ninety-four of the registered patients consented to participate, of whom 55 meeting genetic or biochemical criteria confirming DMD were analyzed. The mean age at the time of the study was 43.6 ± 3.0 years, while at the time of independent ambulation loss it was 10.6 ± 1.5 years and at mechanical ventilation introduction it was 24.1 ± 5.5 years. All were receiving continuous ventilation support, 27 with non-invasive positive pressure ventilation and 28 with tracheal intermittent positive pressure ventilation. Thirty-eight were receiving β-blockers or a renin-angiotensin system inhibitor, while 9 were free from those agents. Forty had maintained oral nutrition. The 55 analyzed patients had survived into their 40s by receiving multidisciplinary intervention. Our findings emphasize the need of future studies to investigate disease modifiers and the mechanism of long-term survival. In addition, establishment of a worldwide care standard with focus on quality of life for adult males with DMD is important.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Conventional multidisciplinary care; Duchenne muscular dystrophy (DMD); Long-term survivor

Mesh:

Year:  2016        PMID: 28003112     DOI: 10.1016/j.nmd.2016.11.012

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  13 in total

1.  Risk Factors for Cardiac and Non-cardiac Causes of Death in Males with Duchenne Muscular Dystrophy.

Authors:  Carol A Wittlieb-Weber; Kenneth R Knecht; Chet R Villa; Chentel Cunningham; Jennifer Conway; Matthew J Bock; Katheryn E Gambetta; Ashwin K Lal; Kurt R Schumacher; Sabrina P Law; Shriprasad R Deshpande; Shawn C West; Joshua M Friedland-Little; Irene D Lytrivi; Michael A McCulloch; Ryan J Butts; David R Weber; Jonathan N Johnson
Journal:  Pediatr Cardiol       Date:  2020-02-03       Impact factor: 1.655

Review 2.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; David Brumbaugh; Laura E Case; Paula R Clemens; Stasia Hadjiyannakis; Shree Pandya; Natalie Street; Jean Tomezsko; Kathryn R Wagner; Leanne M Ward; David R Weber
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

3.  Uncertainty, hope, and coping efficacy among mothers of children with Duchenne/Becker muscular dystrophy.

Authors:  Megan Bell; Barbara B Biesecker; Joann Bodurtha; Holly L Peay
Journal:  Clin Genet       Date:  2019-04-03       Impact factor: 4.438

4.  Preventing Cardiomyopathy in DMD: A Randomized Placebo-Controlled Drug Trial.

Authors:  John P Bourke; Gillian Watson; Stefan Spinty; Andrew Bryant; Helen Roper; Thomas Chadwick; Ruth Wood; Elaine McColl; Kate Bushby; Francesco Muntoni; Michela Guglieri
Journal:  Neurol Clin Pract       Date:  2021-10

Review 5.  Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations.

Authors:  John Bourke; Cathy Turner; William Bradlow; Ashish Chikermane; Caroline Coats; Matthew Fenton; Maria Ilina; Alexandra Johnson; Stam Kapetanakis; Lisa Kuhwald; Adrian Morley-Davies; Ros Quinlivan; Konstantinos Savvatis; Marianela Schiava; Zaheer Yousef; Michela Guglieri
Journal:  Open Heart       Date:  2022-10

Review 6.  Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; Mary K Colvin; Linda Cripe; Adrienne R Herron; Annie Kennedy; Kathi Kinnett; James Naprawa; Garey Noritz; James Poysky; Natalie Street; Christina J Trout; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-02       Impact factor: 44.182

7.  The Relationship Between Bone Mineral Density and Cardiovascular Function in Duchenne Muscular Dystrophy: A Retrospective Cohort Study.

Authors:  Tara Kervin; Mathula Thangarajh
Journal:  PLoS Curr       Date:  2018-03-22

8.  Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.

Authors:  Sven Dittrich; Erika Graf; Regina Trollmann; Ulrich Neudorf; Ulrike Schara; Antje Heilmann; Maja von der Hagen; Brigitte Stiller; Janbernd Kirschner; Robert Dalla Pozza; Wolfgang Müller-Felber; Katja Weiss; Katja von Au; Markus Khalil; Reinald Motz; Christoph Korenke; Martina Lange; Ekkehard Wilichowski; Joseph Pattathu; Friedrich Ebinger; Nicola Wiechmann; Rolf Schröder
Journal:  Orphanet J Rare Dis       Date:  2019-05-10       Impact factor: 4.123

9.  Exploring the acceptability of implantable defibrillators in patients with cardiac dystrophinopathy and carers.

Authors:  Ursula M Hiermeier; Christine Baker; John P Bourke
Journal:  Open Heart       Date:  2020-04-21

10.  Longitudinal Evaluation of Working Memory in Duchenne Muscular Dystrophy.

Authors:  Mathula Thangarajh; Gary L Elfring; Panayiota Trifillis
Journal:  J Clin Med       Date:  2020-09-11       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.